Tag: Vici Venous Stent

VIRTUS 12-month outcomes presented at LINC: Vici stent meets primary endpoints

New 12-month data from the VIRTUS trial demonstrates that patients who were treated with the Vici Venous Stent system (Boston Scientific) for iliac and femoral...

Boston Scientific announces agreement to acquire Veniti

Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for...

Venography and IVUS for the diagnosis and treatment of iliofemoral venous...

The results of the VIRTUS feasibility study—analysing the performance of the Vici venous stent system (Veniti) in achieving patency of venous lesions up to...

IVUS may be a more accurate method than venography for assessing...

Fresh data from the VIRTUS feasibility study presented at the Vascular Interventional Advances (VIVA) annual conference 2016 (18–22 September, Las Vegas, USA) suggest that...

Veniti closes on US$25m from Boston Scientific

Veniti has closed on US$25m in Series D equity financing from Boston Scientific Corporation. The funds will allow Veniti to complete the VIRTUS trial...